Humanised antibodies

US7241877B2 · kind B2 · utility

Assignee

• Celltech R&D Limited · GB

Inventors

• John Robert Adair · Paragon Road, GB
• Diljeet Singh Athwal · London, GB
• John Spencer Emtage · Del Mar, US

Key dates

• Filing date: Nov 7, 2003
• Grant date: Jul 10, 2007
• Expiry date: Apr 17, 2025

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/02
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise donor residues at at least one of positions (1) and/or (3) and (46) and/or (47) or at at least one of positions (46, 48, 58) and (71). The CDR-grafted antibodies are preferably humanized antibodies, having non human, e.g. rodent, donor and human acceptor frameworks, and may be used for in vivo therapy and diagnosis. A generally applicable protocol is disclosed for obtaining CDR-grafted antibodies.